

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number				09/731.872	
Filing Date				December 7, 2000	
First Named Inventor				DUMAS MILNE EDWARDS, et al.	
Art Unit				1645	
Examiner Name				Unassigned	
Attorney Docket Number				78.US3.REG	
Sheet	1	of	3		

[illegible][illegible]

Examiner Signature	<i>Chen</i>	Date Considered	10/15/02
--------------------	-------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/731.872
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 7, 2000
		First Named Inventor	DUMAS MILNE EDWARDS. et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	78.US3.REG
Sheet	2	of	3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CHK	F	DATABASE GENESEQ [Online] AC No. Y76144, 23 March 2000; Ruben S.M., et al.; "Human secreted protein encoded by gene 21"; XP002163702	/
	G	DATABASE GENESEQ [Online] AC No. Z65270, 23 March 2000; Ruben S.M., et al.; "Human secreted protein gene 21"; XP002163703	/
	H	DATABASE EMBL [Online] AC No. AI911546; 30 July 1999; Natl. Cancer Inst.; "ty73d05.x1 NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2284713"; XP002163704	/
	I	DATABASE EMBL [Online] AC No. AI361251; 7 January 1999; Natl. Cancer Inst.; "qy42e02.x1 NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE:2014682"; XP002163705	/
	J	JACOBS, K.A., et al.; "A genetic selection for isolating cDNAs encoding secreted proteins"; Gene, NL, Elsevier Biomedical Press., Amsterdam, Vol. 198, 1 October 1987; pgs. 289-296; XP002045919	/
	K	TASHIRO, K., et al.; "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins"; Science; U.S., American Association for the Advancement of Science; Vol. 261; 30 July 1993; pgs. 600-603; XP000673204	/
	L	LIM, E.M., et al.; "Identification of Mycobacterium tuberculosis DNA Sequences Encoding Exported Proteins by Using phoA Gene Fusions"; Journal of Bacteriology, Jan. 1995, Vol. 177, No. 1; pp. 59-650021-9193/95; XP000560419	/
	M	MIYAKE, et al.; "RP105, a Novel B Cell Surface Molecule Implicated in B Cell Activation, is a Member of the Leucine-Rich Repeat Protein Family"; The Journal of Immunology, pgs. 3333-3340; The American Association of Immunologists; 0022-1767/95	/
	N	TASHIRO, et al.; "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins"; Science, Vol. 261; 30 July 1993; pgs. 600-603	/
	O	JACOBS, et al.; "A Novel Method for Isolating Eukaryotic cDNA Clones Encoding Secreted Proteins"; Dendritic Cells: Antigen Presenting Cells of T and B Lymphocytes; C1-207	/
CHK	P	FUJIWARA, T., et al.; Accession No. D62634; "HUM309B01B Clontech human aorta polyA+ mRNA (#6572) Homo sapiens cDNA clone GEN-309B01 5', mRNA sequence"; XP002032351	/

Examiner Signature	<i>CHK</i>	Date Considered	10/15/02
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
FEB 15 2002
TECH CENTER 1600/2900

RECEIVED
FEB 15 2002
CENTER 1600/2900